Phase III

Related by string. PHASE III * phase : Phase III clinical trials / iii : Star Wars Episode III * Phase III trials . Phase III clinical . pivotal Phase III . Phase III Clinical Trial . Phase III pivotal . Pivotal Phase III . Phase III Trial . randomized Phase III . confirmatory Phase III . Phase III randomized . LibiGel Phase III . Phase III placebo controlled . placebo controlled Phase III *

Related by context. Frequent words. (Click for all words.) 88 Phase II 83 Phase III clinical 81 pivotal Phase III 80 Phase IIb 78 Phase Ib 78 Phase 2b 77 Phase 77 Phase IIb trial 77 Phase 2b trial 76 Phase III trials 76 Phase 2a 76 Phase 1b 76 Phase IIa 76 Phase 2b study 76 Phase 2b clinical 75 Phase IIa clinical 74 Phase 2a clinical 74 Phase III clinical trials 74 Phase IIb clinical 73 Phase IIa trial 73 pivotal Phase 71 clinical trial 68 randomized Phase 67 clinical trials 65 placebo controlled 64 dose escalation study 63 mipomersen 62 dose escalation 62 Phase IV 62 preclinical 62 AP# [003] 61 ASA# 61 randomized placebo controlled 61 T DM1 61 initiate Phase 61 randomized double 60 randomized controlled 60 PRX # 60 XL# [003] 60 double blind placebo 60 investigational drug 60 multicenter 60 perifosine 60 IMGN# 60 eculizumab 60 INCB# [002] 60 carfilzomib 59 IND enabling 59 investigational compound 59 blind randomized placebo 59 randomized clinical 59 laquinimod 59 pharmacokinetic 58 daclizumab 58 NDA submission 58 ofatumumab 58 MGCD# [001] 58 Bronchitol 58 Clinical Trial 58 LymphoStat B 57 lubiprostone 57 RG# [001] 57 HspE7 57 ISIS # 57 blind randomized 57 avanafil 56 ALKS 56 linaclotide 56 Actemra 56 voreloxin 56 Marqibo 56 New Drug Application 56 Clolar 56 oral formulation 56 AMR# 56 AZD# 55 Hematide 55 Investigational 55 RDEA# 55 investigational 55 phase 55 prospective randomized 55 unblinded 55 picoplatin 55 tivozanib 55 Antegren 55 Dacogen 55 MDV# 55 LEVADEX 55 ambrisentan 55 LibiGel 55 satraplatin 55 Marketing Authorization Application MAA 55 Entereg 55 IDX# 55 Nexavar 55 FOLOTYN 55 DSMB 55 confirmatory 55 bapineuzumab 55 Special Protocol Assessment

Back to home page